BackArtiva Biotherapeutics Overview

Artiva Biotherapeutics Long Term Debt

Track Artiva Biotherapeutics's long-term debt ($6.6M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$6.55M
31.64% YoYΔ $-3.03M vs prior year quarter

Peer trimmed avg / median

Loading

Artiva Biotherapeutics Long Term Debt History

Loading

Artiva Biotherapeutics vs. peers: Long Term Debt Comparison

Loading

Artiva Biotherapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Artiva Biotherapeutics (ARTV) FAQ

As of the most recent data (June 2026), ARTV shows a long-term debt of $6.6M. That compares with $9.6M in the prior-year period — down 31.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ARTV's long-term debt is now $6.6M (was $9.6M) — a 31.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Artiva Biotherapeutics is outperforming or lagging.

Tracking ARTV's long-term debt over time shows whether Artiva Biotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $6.6M That compares with $9.6M in the prior-year period — down 31.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Artiva Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $6.6M) with ownership activity and broader fundamentals.